BioAge halts obesity drug trial after safety concerns
BioPharma Dive - 07-Dec-2024Liver enzyme spikes in participants prompt a major setback for the biotech firm
Join the club for FREE to access the whole archive and other member benefits.
Reporter at BioPharma Dive
Gwendolyn is a reporter at BioPharma Dive, where she covers biotech startups, venture capital, and the ecosystem supporting them. She previously wrote Bay Briefing, the San Francisco Chronicle’s main weekday newsletter, and reported on COVID-19 and healthcare business for the Houston Chronicle. Outside of journalism, Gwendolyn co-directs the AAJA Voices Fellowship and teaches at the California Scholastic Press Association's summer workshop. She holds degrees in history and sociology from the University of California, Santa Barbara.
Visit website: https://www.biopharmadive.com/editors/gwu/
See also
A news publisher offering in-depth coverage of the pharmaceutical and biotech industries
Details last updated 08-Dec-2024
Liver enzyme spikes in participants prompt a major setback for the biotech firm